SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults
Matthew E. Levy, Evanette Burrows, Vanessa Chilunda, Pamala A. Pawloski, Phillip Heaton, Joseph J. Grzymski, Jason D. Goldman, Lisa M. McEwen, Dana Wyman, Andrew Dei Rossi, Hang Dai, Magnus Isaksson, Nicole Washington, Tracy Basler, Kevin Tsan, Jason Nguyen, Jimmy M. Ramirez, Efren Sandoval, William Lee, James T. Lu, Shishi Luo
Abstract
Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakCohortAntiviral treatmentRitonavirCohort studyEmergency medicineIntensive care medicineInternal medicineVirologyViral loadVirusInfectious disease (medical specialty)OutbreakAntiretroviral therapyChronic hepatitisDiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research